BioSpace News Archive

While gene therapies for treating sickle cell disease are promising, they will only be cost effective in the U.S. if priced below $2 million, according to a new modeling analysis.

The French drugmaker is buying California-based biotech Inhibrx to gain access to its clinical-stage drug candidate for alpha-1 antitrypsin deficiency, as it tries winning over investors with potential blockbusters.

Sequana Medical NV announces that an independent Data and Safety Monitoring Board approved the start of the randomized cohort in MOJAVE, the US Phase 1/2a study of DSR 2.0 for treatment of patients with diuretic-resistant heart failure, following review of the safety data reported from the non-randomized cohort.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, invites to a conference call on the updated data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma.

Baird Medical Devices, Inc. announced that it has performed its first thyroid MWA procedure in the United States since obtaining registration clearance from the U.S. Food and Drug Administration on November 22, 2023.

HippoFi’s biotechnology business PUR Biologics, proudly announces Scott Bauccio as its new Head of Sales.

Synthego and SeQure Dx have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions.

3M reported fourth-quarter and full-year 2023 results and provided its 2024 financial outlook.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.

Johnson & Johnson announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer.